AI agent beats GPT-4: oncology decisions jump from 30% to 87% accuracy

An innovative AI agent has significantly outperformed GPT-4 in oncology decision-making, increasing accuracy from 30.3% to 87.2%. Evaluated on 20 realistic multimodal patient cases, the system autonomously applied appropriate tools with 87.5% accuracy, reached correct clinical conclusions in 91.0% of cases, and accurately cited relevant oncology guidelines 75.5% of the time.

The AI agent integrates advanced technologies, including vision transformers, to detect microsatellite instability and mutations such as KRAS and BRAF from histopathology slides. Upon receiving clinical vignettes and related questions, it autonomously selects and applies relevant tools to derive supplementary insights about the patient’s condition.

This breakthrough demonstrates the potential of combining multimodal data analysis with autonomous tool selection to enhance clinical decision-making in oncology. The system’s ability to accurately interpret complex patient data and reference guidelines marks a significant advancement over GPT-4’s standalone performance.

“Compared to GPT-4 alone, the integrated AI agent drastically improved decision-making accuracy from 30.3% to 87.2%,” highlighting the leap in precision.

With its high accuracy and autonomous operation, this AI agent could transform oncology diagnostics and treatment planning, offering clinicians a powerful tool to improve patient outcomes.

An advanced AI agent outperforms GPT-4 in oncology decision-making, boosting accuracy from 30% to 87%. Tested on 20 multimodal patient cases, it autonomously applied tools, reached correct clinical conclusions in 91% of cases, and cited relevant guidelines 75.5% of the time.